Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Eton Pharmaceuticals (ETON) Income from Continuing Operations (2019 - 2025)

Eton Pharmaceuticals' Income from Continuing Operations history spans 7 years, with the latest figure at 1927000.0 for Q3 2025.

  • For Q3 2025, Income from Continuing Operations fell 407.34% year-over-year to 1927000.0; the TTM value through Sep 2025 reached 6682000.0, down 21.91%, while the annual FY2024 figure was 3823000.0, 308.44% down from the prior year.
  • Income from Continuing Operations for Q3 2025 was 1927000.0 at Eton Pharmaceuticals, up from 2585000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 5116000.0 in Q1 2021 and bottomed at 6094000.0 in Q3 2021.
  • The 5-year median for Income from Continuing Operations is 1572000.0 (2025), against an average of 1148368.42.
  • The largest annual shift saw Income from Continuing Operations surged 392.62% in 2023 before it plummeted 407.34% in 2025.
  • A 5-year view of Income from Continuing Operations shows it stood at 1039000.0 in 2021, then fell by 12.22% to 912000.0 in 2022, then tumbled by 347.37% to 2256000.0 in 2023, then skyrocketed by 73.49% to 598000.0 in 2024, then crashed by 222.24% to 1927000.0 in 2025.
  • Per Business Quant, the three most recent readings for ETON's Income from Continuing Operations are 1927000.0 (Q3 2025), 2585000.0 (Q2 2025), and 1572000.0 (Q1 2025).